Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations
Due to groundbreaking developments and continuous progress, the treatment of stage IV non-small cell lung cancer (NSCLC) has become an exciting but increasingly challenging task. This applies in particular to the subgroup of NSCLC with oncogenic driver alterations. While the treatment of epidermal g...
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
THE HEALTHBOOK COMPANY LTD.
2020-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Acceso en liña: | https://doi.org/10.36000/hbT.OH.2020.05.019 |